Cargando…

Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey

PURPOSE: Clostridioides difficile infection (CDI) is the most prevalent cause of nosocomial infectious diarrhea in Canada and is highly correlated with antibiotic use and contact with health care facilitates. The often-severe symptoms of CDI include diarrhea, dehydration, and abdominal pain. Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Vent-Schmidt, Jens, Attara, Gail P, Lisko, Daniel, Steiner, Theodore S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954101/
https://www.ncbi.nlm.nih.gov/pubmed/32021115
http://dx.doi.org/10.2147/PPA.S229539
_version_ 1783486737834573824
author Vent-Schmidt, Jens
Attara, Gail P
Lisko, Daniel
Steiner, Theodore S
author_facet Vent-Schmidt, Jens
Attara, Gail P
Lisko, Daniel
Steiner, Theodore S
author_sort Vent-Schmidt, Jens
collection PubMed
description PURPOSE: Clostridioides difficile infection (CDI) is the most prevalent cause of nosocomial infectious diarrhea in Canada and is highly correlated with antibiotic use and contact with health care facilitates. The often-severe symptoms of CDI include diarrhea, dehydration, and abdominal pain. Patients often relapse following symptom resolution, resulting in increased morbidity. Previous research on the impact of CDI centered around the health-care system, clinician perspectives and economic burden, but not on patient experiences. The purpose of this study was to understand the impact of CDI on patients in Canada. METHODS: The Gastrointestinal Society conducted online surveys and gathered data from 167 qualifying participants, who were either patients or their non-treating caregivers. Quantitative parameters were analyzed by descriptive and comparative statistics and contextualized with qualitative insights derived from thematic analysis of open-ended questions. RESULTS: Our findings, which focused on clinical parameters such as prior exposure to health-care settings, antibiotic use, and patients’ symptoms, mirrored findings from previous research. Interestingly, most surveyed respondents experienced delays in diagnosis and treatment; 29% waited 6–30 days and 10% over 30 days. This delayed diagnosis was further complicated by the report that 62% of respondents did not experience symptom resolution within 7 days of initiating treatment. Importantly, our results suggest a lasting impact after the resolution of CDI and we saw a reduction of self-assessed quality of life from prior to post CDI. Patients’ priorities regarding their experience with CDI focused around concerns about the health-care system, particularly time to diagnosis and treatment, concerns about antibiotic usage and needs from health-care providers. CONCLUSION: This is the first Canadian report on patients’ experience with CDI. Our data highlight the symptom-related impact on patients and the long-lasting effect on the quality of life including emotional impact. Reducing time to diagnosis and improving patient education are important priorities to attenuate the impact on patients.
format Online
Article
Text
id pubmed-6954101
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69541012020-02-04 Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey Vent-Schmidt, Jens Attara, Gail P Lisko, Daniel Steiner, Theodore S Patient Prefer Adherence Original Research PURPOSE: Clostridioides difficile infection (CDI) is the most prevalent cause of nosocomial infectious diarrhea in Canada and is highly correlated with antibiotic use and contact with health care facilitates. The often-severe symptoms of CDI include diarrhea, dehydration, and abdominal pain. Patients often relapse following symptom resolution, resulting in increased morbidity. Previous research on the impact of CDI centered around the health-care system, clinician perspectives and economic burden, but not on patient experiences. The purpose of this study was to understand the impact of CDI on patients in Canada. METHODS: The Gastrointestinal Society conducted online surveys and gathered data from 167 qualifying participants, who were either patients or their non-treating caregivers. Quantitative parameters were analyzed by descriptive and comparative statistics and contextualized with qualitative insights derived from thematic analysis of open-ended questions. RESULTS: Our findings, which focused on clinical parameters such as prior exposure to health-care settings, antibiotic use, and patients’ symptoms, mirrored findings from previous research. Interestingly, most surveyed respondents experienced delays in diagnosis and treatment; 29% waited 6–30 days and 10% over 30 days. This delayed diagnosis was further complicated by the report that 62% of respondents did not experience symptom resolution within 7 days of initiating treatment. Importantly, our results suggest a lasting impact after the resolution of CDI and we saw a reduction of self-assessed quality of life from prior to post CDI. Patients’ priorities regarding their experience with CDI focused around concerns about the health-care system, particularly time to diagnosis and treatment, concerns about antibiotic usage and needs from health-care providers. CONCLUSION: This is the first Canadian report on patients’ experience with CDI. Our data highlight the symptom-related impact on patients and the long-lasting effect on the quality of life including emotional impact. Reducing time to diagnosis and improving patient education are important priorities to attenuate the impact on patients. Dove 2020-01-06 /pmc/articles/PMC6954101/ /pubmed/32021115 http://dx.doi.org/10.2147/PPA.S229539 Text en © 2020 Vent-Schmidt et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Vent-Schmidt, Jens
Attara, Gail P
Lisko, Daniel
Steiner, Theodore S
Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey
title Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey
title_full Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey
title_fullStr Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey
title_full_unstemmed Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey
title_short Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey
title_sort patient experiences with clostridioides difficile infection: results of a canada-wide survey
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954101/
https://www.ncbi.nlm.nih.gov/pubmed/32021115
http://dx.doi.org/10.2147/PPA.S229539
work_keys_str_mv AT ventschmidtjens patientexperienceswithclostridioidesdifficileinfectionresultsofacanadawidesurvey
AT attaragailp patientexperienceswithclostridioidesdifficileinfectionresultsofacanadawidesurvey
AT liskodaniel patientexperienceswithclostridioidesdifficileinfectionresultsofacanadawidesurvey
AT steinertheodores patientexperienceswithclostridioidesdifficileinfectionresultsofacanadawidesurvey